Compositions and methods for treatment of kidney disorders
AssigneeVectus Biosystems Pty Limited
InventorKaren Annette Duggan
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions.
Claims9
A method of prophylactic or therapeutic treatment of chronic kidney disease in a subject, the method comprising administering to the subject at risk of developing chronic kidney disease, or to a subject having chronic kidney disease, a composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) or one or more functional VIP fragments selected from VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conservative substitutions thereof, optionally in combination with a pharmaceutically acceptable carrier.
A method of prophylactic or therapeutic treatment of kidney failure in a subject, the method comprising administering to the subject at risk of developing kidney failure, or to a subject having kidney failure, a composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) or one or more functional VIP fragments selected from VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conservative substitutions thereof, optionally in combination with a pharmaceutically acceptable carrier.
A method of prophylactic or therapeutic treatment of kidney fibrosis in a subject, the method comprising administering to the subject at risk of developing kidney fibrosis, or to a subject having kidney fibrosis, a composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) or one or more functional VIP fragments selected from VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conservative substitutions thereof, optionally in combination with a pharmaceutically acceptable carrier.
A method of reducing the levels of pro-fibrotic mediators, inhibiting or reducing the production of pro-fibrotic mediators, reducing collagen formation, or enhancing collagen degradation in the kidney, in a subject at risk of developing, or having established kidney disease, kidney failure and/or kidney fibrosis, the method comprising administering to the subject a composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) or one or more functional VIP fragments selected from VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conservative substitutions thereof, optionally in combination with a pharmaceutically acceptable carrier.
8-19. (canceled)
Dependencies are inferred from the claim text.